Outlook wins FDA appeal for twice‑rejected eye drug Lytenava, eyes June 2026 BLA resubmission on May 27, 2026 Biological Factors Class 1 resubmission FDR Formal Dispute Resolution ( Lytenava nAMD New-onset refractory status epilepticus Outlook Therapeutics PDUFA United States Food and Drug Administration +
KOL Bulletin: ONS-5010's Bigger Opportunity May Lie Outside the US After FDA's Third CRL, KOL Says on February 01, 2026 IL31RA gene KOL Lytenava Market Outlook Therapeutics ' United States Food and Drug Administration wet AMD +
Outlook Therapeutics Faces New FDA Setback for First Ophthalmic Avastin Formulation on August 29, 2025 Attitude Avastin bevacizumab Blackfoot language Eight Glycogen storage disease type II Lytenava New-onset refractory status epilepticus rejection United States Food and Drug Administration +